A proposed mechanism of production of the autoimmune and lymphoproliferative side-effects of beta-adrenergic-site-blocking drugs and hydantoin anticonvulsants.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000818:Animals; D001327:Autoimmune Diseases / Q000139:chemically induced*; D002273:Carcinogens; D000242:Cyclic AMP / Q000378:metabolism; D004983:Ethanolamines / Q000633:toxicity; D005260:Female; D006801:Humans; D008206:Lymphatic Diseases / Q000139:chemically induced*; D008214:Lymphocytes / Q000378:metabolism; D008223:Lymphoma / Q000139:chemically induced; D008297:Male; D051379:Mice; D010672:Phenytoin / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D002273:Carcinogens; D004983:Ethanolamines; D010672:Phenytoin; D000242:Cyclic AMP